top of page

Stage 1 Lung Cancer: Five Sessions of ETHOS SBRT When Surgery Was Not an Option

14 minutes ago
2 min read

A diagnosis of early-stage lung cancer can offer the opportunity for treatment with curative intent. But what happens when a patient's health makes surgery too risky?


A gentleman from Jakarta came to me after experiencing a persistent cough. During lung screening, a solitary lung nodule measuring approximately 3 cm was identified. Further assessment, including PET/CT, showed stage 1 lung cancer.


Why surgery was not suitable


Surgery is an important treatment option for stage 1 lung cancer in patients who are medically fit. This gentleman, however, had diabetes, hypertension and heart failure, and was taking several medications. Following assessment of his overall health and surgical risk, he was considered medically unfit for an operation.


I therefore offered stereotactic body radiotherapy, or SBRT, using ETHOS.


Five treatment sessions


SBRT delivers highly focused radiation to the tumour while carefully limiting the dose to surrounding healthy tissues.


He completed five daily radiotherapy sessions, each taking approximately 10 minutes. This schedule and treatment time describe his individual course of treatment.


His three-month scan


The comparison shows his scan before treatment on the left and his follow-up scan three months after SBRT on the right.


Stage 1 lung cancer PET/CT before ETHOS SBRT on the left and three months after treatment on the right, with residual scarring and no detectable activity at the treated lesion.

At this assessment, the previously active lung lesion had resolved, with residual scarring and no detectable activity at the treated site. This was a very encouraging early response. Follow-up remains essential to assess longer-term tumour control and monitor changes in the treated lung.


When can SBRT be considered?


SBRT is an established treatment option for selected patients with early-stage lung cancer who are medically inoperable. It can also be discussed with patients who decline surgery after a thorough assessment and informed discussion of their options.


The decision depends on the tumour's size and location, lung function, other medical conditions and the patient's preferences. Surgery remains an important option for medically fit patients.


For this gentleman, personalised treatment meant choosing an approach that addressed his cancer while taking his heart failure and other health conditions into account.


Being unable to undergo surgery does not mean there are no treatment options.


Dr Malwinder Singh — The Bald Oncologist


 
 
 

Comments


bottom of page